New Nonhormonal Options for Menopausal Hot Flashes: A 2023–2026 Review of New VMS Drugs
Hot flashes are a real physical experience. Their pattern and impact are more useful to discuss than guessing a hormone number.

In this article
Evidence boundaries first
This article distinguishes between completed randomized controlled trials, regulatory-agency drug labels, guidelines, and reports presented at academic meetings. Indications and monitoring requirements for approved drugs should be checked against the latest prescribing information. Investigational drugs and conference abstracts indicate research directions only; they do not mean efficacy has been established, and their findings cannot be extrapolated into routine treatment recommendations for people in China.
1. Hot flashes and night sweats: why were there only "two old paths"?
About seven in ten women going through menopause are troubled by hot flashes and night sweats; as many as eight in ten experience them at some point. Sudden facial flushing, heat in the upper body, and sweating appear without warning and subside on their own after a few minutes. In severe cases they occur dozens of times a day and wake someone night after night. They undermine sleep, mood, and performance at work, yet many people silently endure them.
For decades there were really only two options: either use menopausal hormone therapy (MHT) to replace estrogen, or "make do" by using a drug originally intended for depression, such as low-dose paroxetine, to suppress symptoms. Some people have contraindications or concerns about the former; the latter has limited efficacy. Only after researchers worked out what actually happens in the brain during a hot flash did a third, and then a fourth, path become available.
From 2023 to 2025, the US FDA approved two new nonhormonal drugs targeting this neural pathway in succession. By 2026, an antibody approach and investigational medicines developed in China had also begun to emerge. This article reviews the background and development of this wave of "new nonhormonal approaches" from 2023–2026.
2. Background and mechanism: where does the "burn" of a hot flash begin?

Rice terraces in Bali, Indonesia, photographed on location; the image is unrelated to the drug evidence.
Before discussing new drugs, we need to understand how this distressing symptom arises. The core manifestations of vasomotor symptoms (VMS) are hot flashes and night sweats: sudden facial flushing, upper-body heat, and sweating that subside on their own after a few minutes, but may occur dozens of times a day and wake someone night after night in severe cases. Their root lies in disruption of the hypothalamic thermoregulatory center's "set point" after estrogen withdrawal: even though the body is not hot, it mistakenly initiates a heat-dissipation response.
For decades, the reason for this "disruption" remained a mystery. Treatment was limited to "replacing estrogen" or "suppressing symptoms." An important development over the past decade has been the identification of a group of neurons in the hypothalamic arcuate nucleus called KNDy neurons (named for the three substances they secrete: kisspeptin, neurokinin B, and dynorphin). In a normal estrogen environment, KNDy neurons are moderately suppressed. Once estrogen is withdrawn, they become excessively activated "out of control" and release too much neurokinin B (NKB). NKB acts on thermoregulatory neurons in the hypothalamic organum vasculosum of the lamina terminalis that carry NK3 receptors, mistakenly sounding the alarm "too hot—dissipate heat now." Blood vessels in the skin dilate and sweating starts, so you feel that wave of heat.
A target identified means a "precise direction" for drugs
A 2026 review in Nature Reviews Endocrinology systematically mapped the pathway from KNDy neurons to NK3 receptors. Its significance is that VMS now has a defined target for drug development. This led to NK3 receptor antagonists: rather than directly replacing estrogen, they block NKB from binding to NK3 receptors and reduce the abnormal signal. These are the first nonhormonal therapies designed specifically to target the neurobiology of VMS rather than simply replace hormones. This also explains why they are especially important for people who "cannot use hormones."
Keep this distinction in mind: MHT aims to "replace estrogen from outside the body," with additional effects on hot flashes, bone protection, and vaginal dryness. NK receptor antagonists take a different route: they "adjust the body's temperature switch in the brain," and contain neither estrogen nor progesterone. The two approaches do not conflict, but they suit very different patient profiles. When hormones are inadvisable because of a history of breast cancer, thrombosis risk, migraine with aura, liver disease, or similar factors, NK antagonists take up the baton.
Why does "the thermoregulatory center become disrupted as soon as estrogen is withdrawn"? The answer begins with the anatomical location of KNDy neurons: they lie next to the hypothalamic arcuate nucleus that regulates the reproductive axis. Under normal circumstances they are suppressed by estrogen negative feedback and also participate in the rhythm of reproductive hormones. With sufficient estrogen, this negative feedback keeps NKB release low. Once ovarian function declines and estrogen drops precipitously, the feedback is removed. KNDy neurons fire faster and also undergo structural "hypertrophy and proliferation," releasing a sustained, massive amount of NKB. This pathway normally serves reproduction, but during menopause it "misfires" on thermoregulation. This also explains why hot flashes often appear at the earliest stage of menstrual irregularity and may begin much earlier than the final menstrual period and last longer. Explaining the mechanism matters because it shows that these new drugs target an abnormal signaling chain supported by experimental and clinical research.
Access note for readers in China
Approval information in this article for the two NK receptor antagonists, fezolinetant and elinzanetant, comes mainly from US FDA, UK MHRA, and EU regulatory milestones (2023–2025). Marketing timelines, brand names, reimbursement, and prescribing rules differ between countries and regions. In mainland China, introduction, pricing, and insurance coverage for these drugs are still progressing. Actual availability should be checked against the latest announcements from China's National Medical Products Administration and the pharmacy formulary at your treating doctor's institution. Wherever you live, the central principle is the same: a doctor should first assess whether it is suitable, before you discuss "which one to use and how to monitor it."
~70%
Women going through menopause affected by vasomotor symptoms; the proportion can reach 80%
Week 1
Trials of some NK receptor antagonists have observed improved hot-flash frequency by the first week; the onset speed of different drugs cannot be ranked directly using cross-trial numbers
2 drugs
"First-in-class" nonhormonal targeted drugs (NK receptor antagonists) approved in 2023 and 2025
3. Evidence review: what exactly are these two "first-in-class" drugs?

Lake beside Ulun Danu Temple in Bali, Indonesia, photographed on location; the image is unrelated to the drug evidence.
From 2023 to 2025, the US FDA successively approved two nonhormonal drugs specifically targeting the neural pathway for VMS. Their mechanisms, evidence, and precautions differ.
The first: fezolinetant (brand name Veozah)
Approved in May 2023, it was the world's first selective NK3 receptor antagonist and the first nonhormonal drug designed specifically for VMS. The dose is 45 milligrams orally once a day. Its key evidence comes from the SKYLIGHT phase III trial series (published in The Lancet in 2023, Journal of Clinical Endocrinology & Metabolism in 2023, and Obstetrics & Gynecology in 2023): in postmenopausal women with moderate-to-severe hot flashes, daily hot-flash frequency fell about 65% more than with placebo, severity also decreased significantly, and onset was rapid, with a difference felt within about a week.
There is, however, an essential safety label to acknowledge: in December 2024, after postmarketing surveillance identified rare but serious cases of liver injury, the FDA added a boxed warning for fezolinetant. Liver function must therefore be checked before treatment, monthly in months 1, 2, and 3, and again in months 6 and 9. Stop the drug if transaminases exceed 5 times the upper limit of normal, or exceed 3 times the limit while bilirubin exceeds 2 times the limit. Do not initiate it if baseline transaminases or bilirubin already exceed 2 times the upper limit. In addition, it is a CYP1A2 substrate: blood levels increase when taken with certain inhibitors such as fluvoxamine and ciprofloxacin. It is contraindicated in known cirrhosis. Common adverse reactions include abdominal pain, diarrhea, insomnia, back pain, hot flashes, and elevated transaminases.
The second: elinzanetant (brand name Lynkuet)
Approved by the FDA on October 24, 2025 (after the UK's MHRA became the first regulator worldwide to approve it in July 2025), it was developed by Bayer and is the first dual NK1/NK3 receptor antagonist. It addresses temperature through NK3 and may improve sleep and mood via NK1 (the substance P pathway). The dose is 120 milligrams once daily at bedtime. Evidence comes from the OASIS trial series. OASIS 1 and 2 (JAMA, August 2024; 26 weeks; women aged 40–65) showed reductions in both frequency and severity. OASIS 3 (JAMA Internal Medicine, September 2025; 52 weeks; 628 participants) showed that by week 12, VMS frequency and severity fell nearly 74% more than with placebo. OASIS 4 (New England Journal of Medicine, June 2025) specifically included women suffering from hot flashes while receiving endocrine therapy for breast cancer. Over 52 weeks they had about 7 fewer hot flashes per week than the placebo group, with improvement in sleep and quality of life.
Elinzanetant's safety profile: a "lighter" liver burden
A pooled safety analysis of four placebo-controlled trials presented at the 2026 ACOG Annual Meeting found no new safety signals with elinzanetant. The most common adverse reaction was headache (approximately 7%–8%), and no hepatotoxicity occurred among healthy women in the trials. Liver monitoring is therefore lighter than for fezolinetant: one baseline test and a repeat at about month 3. There is currently no boxed warning. Pregnancy is a contraindication. It is also on the US National Comprehensive Cancer Network (NCCN) survivorship recommendations based on the robust OASIS 4 evidence, filling a gap in safe options for breast cancer patients who have long had few choices.
A "long-standing" option: paroxetine 7.5 milligrams
Before NK antagonists, the only nonhormonal prescription medicine approved on-label for VMS was low-dose paroxetine (paroxetine 7.5 milligrams, brand name Brisdelle), approved in 2013. It is an SSRI antidepressant that helps hot flashes but is less effective overall than the newer NK antagonists. An important caution: paroxetine inhibits CYP2D6 and may weaken tamoxifen efficacy when used together, so coadministration in breast cancer patients requires care.
| Drug (generic name) | Mechanism | Year approved | Key characteristics | Main monitoring/precautions |
|---|---|---|---|---|
| Paroxetine 7.5 mg | SSRI (low dose) | 2013 | Only antidepressant on-label for VMS; relatively modest efficacy | Avoid with tamoxifen (CYP2D6) |
| Fezolinetant | Selective NK3 receptor antagonist | 2023 | First nonhormonal targeted VMS drug; frequency falls about 65% more than placebo; onset ~1 week | Boxed warning for liver injury; baseline + liver function at months 1/2/3/6/9 |
| Elinzanetant | Dual NK1/NK3 antagonist | 2025 | First dual NK antagonist; frequency falls nearly 74% more than placebo; also improves sleep/mood | Baseline + liver function at about month 3; no boxed warning; contraindicated in pregnancy |
Look at the table as a whole: the three drugs share the features "nonhormonal, oral, for moderate-to-severe hot flashes." They differ in mechanistic specificity, degree of efficacy, and monitoring burden. They are not interchangeable substitutes; instead, they give people with different concerns more options—some fear liver monitoring, some fear hormones, some care more about sleep—so choices can be "tailored."
4. Risks and benefits: what is "new" about these drugs, and where are the limits?

Raja Ampat Islands, Indonesia, photographed on location; the image is unrelated to the drug evidence.
Viewed together, the value and limitations of these two new drugs are clear.
Tangible benefits
First, they contain no hormones, naturally avoiding concerns related to estrogen such as thrombosis and breast cancer, and offer long-awaited new options for people with "hormone contraindications or who do not want hormones." Second, they act quickly (about 1 week), sooner than hormones and antidepressants. Third, they are an important addition for people with MHT contraindications: a history of breast cancer, thrombosis, migraine with aura, liver disease, or a recent cardiovascular event. Fourth, elinzanetant additionally improves sleep and mood, benefits that are independent of hot-flash reduction.
Boundaries that must be made clear
First, the liver-monitoring burden of fezolinetant is a real barrier; some people choose another approach because they do not want frequent blood tests. Second, both drugs require a prescription, some regions require prior authorization, and cost and access are still being rolled out (insurance coverage was gradually taking effect in 2026, but some plans still list "limited distribution"). Third, they are not a "cure": symptoms may return after stopping, and they do not address reduced bone density or vaginal dryness, among other issues (these remain areas for MHT or local estrogen). Fourth, for people suitable for MHT, MHT has the highest overall efficacy (about 75%) and can also protect bone and ease genitourinary symptoms. They should not abandon it blindly just because "a new drug has arrived."
Who is more likely to benefit from these two classes of new drugs?
Simply put: for people with a hormone contraindication or who do not want hormones, moderate-to-severe hot flashes, and willingness to accept the required monitoring, NK receptor antagonists should be considered first. If symptoms are mild or anxiety/depression is also present, SSRIs/SNRIs may address both. If night sweats predominate alongside pain, a doctor may add gabapentin, a mood-stabilizing medicine (taken at night). For people suitable for MHT, its combined benefits remain the preferred choice. New drugs mean "one more appropriate option," not "a replacement for every older option."
5. Clinical recommendations: turn "I want to try a new drug" into "Should I use one?"

Mount Bromo, East Java, Indonesia, photographed on location; the image is unrelated to the drug evidence.
More valuable than "I heard there is a new drug" is the concrete question "Is it suitable for me?" Here are several practical principles:
- First quantify severity with a diary. Record daily hot-flash frequency, severity (mild/moderate/severe), and whether sleep is interrupted for one or two weeks. Do not decide based only on "I feel very bothered," and do not force yourself to endure it because "I can still cope." Data help your doctor assess whether your symptoms are mild or moderate-to-severe.
- Clarify first whether MHT is contraindicated for you. A history of breast cancer or thrombosis, migraine with aura, uncontrolled hypertension, active liver disease, or a recent cardiovascular event—under these circumstances a nonhormonal route (especially an NK antagonist) is often more suitable. Conversely, if you have no contraindications and also want bone protection or relief from vaginal dryness, MHT's combined benefits are still worth discussing seriously.
- If you want an NK antagonist, ask about monitoring first. For fezolinetant in particular, confirm you are willing and able to follow the liver-monitoring schedule of "baseline—monthly for the first 3 months—months 6 and 9." If frequent blood tests concern you, discuss elinzanetant or another approach with your doctor.
- Breast cancer patients must make decisions jointly with their oncology team. Elinzanetant has OASIS 4 evidence and is included in NCCN guidance, but do not bypass your cancer treatment plan and add any hot-flash medicine on your own, especially during endocrine therapy when drug interactions matter.
- Watch for drug interactions. Fezolinetant is a CYP1A2 substrate, and some inhibitors raise blood concentrations. Paroxetine may weaken tamoxifen efficacy when used with it. Bring your doctor a full list of all current medicines, including traditional Chinese medicines and supplements.
- Manage sleep and mood together. If hot flashes mainly destroy sleep, elinzanetant's sleep benefits or adding gabapentin at night may address the problem better than simply suppressing hot flashes. Do not focus only on the "number of episodes."
- Do not suddenly stop antidepressant-class medication. If you already use an SSRI/SNRI for hot flashes or mood, reduce the dose gradually when stopping to avoid withdrawal reactions. This, too, is something to adjust "together with your doctor," not decide yourself.
- Bring questions to your appointment. Before going, consider: Which risk group do I belong to? Is a new drug suitable for me? How will monitoring work, and will insurance cover it? Does it conflict with my current medication? Writing these questions down is more likely to get you a "tailored" plan than arriving empty-handed.
- Menopause management is more than "putting out the fire." Bone density, lipids, vaginal lubrication, and mood should all be on the same checklist. A single hot-flash drug cannot complete the entire menopause health picture.
- A new drug is no excuse to "stop changing your lifestyle." Whichever route you choose, it is worthwhile to avoid clear hot-flash triggers: alcohol, caffeine, spicy foods, and overheated environments are commonly mentioned. Regular exercise, weight loss, and relaxation training cannot directly "put out the fire," but can reduce the overall burden and improve sleep. Treat them as a layer alongside medication, rather than waiting for a drug to carry the burden for you.
Which "next generation" candidates are still in the pipeline?
Developments in 2026 go beyond the two approved drugs. AbCellera reported phase II results for the NK3 receptor antibody ABCL635 (August 2026); this remains investigational and must not be regarded as an approved treatment. China is also advancing its own work: phase II results for Gensci's selective NK3 receptor antagonist GS1-144 (Gensci074) in Chinese postmenopausal women were published in Menopause (2025), offering early clinical evidence in a Chinese population. In addition, the HIGHLIGHT 1 trial of fezolinetant for hot flashes associated with endocrine treatment for breast cancer is ongoing. An early-2026 study also linked "higher insulin levels in midlife" with "earlier and longer-lasting hot flashes," but this is an observational association and does not yet prove that metabolic management can prevent hot flashes. At this stage, these findings should be understood as leads for further research.
6. A quick literature review for physician readers
Since many readers of this publication are clinical colleagues, the key evidence above is gathered here under "mechanism—approved—investigational" for quick reference:
- Mechanism review: Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation. Nat Rev Endocrinol. 2026 (KNDy→NK3R pathway; fezolinetant approved in 2023, elinzanetant in 2025; sleep mechanism of dual NK1/NK3 antagonism).
- Fezolinetant: Lederman S et al., SKYLIGHT 1, Lancet 2023; Johnson KA et al., J Clin Endocrinol Metab 2023; Neal-Perry G et al., Obstet Gynecol 2023 (moderate-to-severe VMS, frequency falls about 65% more than placebo, onset ~1 week); FDA boxed warning for liver injury, December 2024; monitoring: baseline—months 1/2/3—months 6/9 liver function.
- Elinzanetant: Pinkerton JV et al., OASIS 1 & 2, JAMA 2024-08; OASIS 3, JAMA Intern Med 2025-09 (52 weeks, nearly 74% greater reduction by week 12); OASIS 4, NEJM 2025-06 (VMS associated with breast cancer endocrine therapy, about 7 additional fewer episodes per week); pooled safety (4 RCTs), ACOG Annual Meeting 2026-05; FDA approval 2025-10-24; first global approval by MHRA 2025-07.
- Established nonhormonal option: Paroxetine 7.5 mg (Brisdelle), FDA 2013, the only SSRI with an on-label VMS indication; venlafaxine, desvenlafaxine, escitalopram, gabapentin, oxybutynin, and others are commonly used off-label.
- Investigational pipeline: AbCellera ABCL635 (NK3R antibody), successful phase II in 2026-08; Gensci GS1-144/Gensci074 (selective NK3R antagonist), phase II in a Chinese population, Menopause 2025; HIGHLIGHT 1 (fezolinetant for VMS associated with breast cancer endocrine therapy), ongoing; association between midlife insulin levels and early hot flashes (early 2026).
- Landscape summary: At the 2026 ENDO meeting, three FDA-approved nonhormonal VMS therapies were grouped together: paroxetine, fezolinetant, and elinzanetant. Liver monitoring and individualized selection were emphasized for all.
7. Bring the "new approach" back to your situation

Lake Toba, North Sumatra, Indonesia, photographed on location; the image is unrelated to the drug evidence.
The conclusion is clear: yes, there are new approaches—and more than one. Fezolinetant in 2023 and elinzanetant in 2025 turned "nonhormonal, precise adjustment of the temperature switch" from an idea into a prescription. By 2026, an antibody approach and a Chinese NK3 antagonist had also begun to emerge. For people such as "my mother had thrombosis and I dare not touch hormones," this is genuinely a newly opened door.
But "breathing a sigh of relief" does not mean "charging ahead with your eyes closed." Each of these two new drugs has a threshold: fezolinetant requires adherence to a liver-monitoring schedule, while elinzanetant is less burdensome but still requires a prescription and follow-up. They address one target—hot flashes—not the entire menopause experience. If you are reading this as someone troubled by hot flashes or a doctor helping someone make a decision, remember three points. First, people who cannot or do not want to use hormones now have a genuinely suitable new option and need not simply endure symptoms. Second, a new drug is "one more appropriate option," not "a universal remedy replacing MHT"; what matters is suitability. Third, the final decision belongs in a discussion that takes your risks, feasibility of monitoring, and overall menopause care into account, not in a passing remark: "I heard about a new drug."
The questions to raise should be straightforward: Which group do I belong to? Is a new drug suitable for me? How will monitoring work, and will insurance cover the cost? Taking these three questions to your doctor is the real value this wave of 2023–2026 drug advances can offer you. May this "new nonhormonal approach" ultimately illuminate your clear-eyed, proactive relationship with your own health.
Disclaimer:
This article is for health education and is based on public literature, guidelines, and drug labels available through October 2026. It is not individualized medical advice, nor an endorsement of any medication. Drugs mentioned, including brand names, are provided only to help with identification and discussion. Whether to use them must be decided jointly by a qualified doctor, considering personal medical history, contraindications, concomitant medication, and the regulatory and reimbursement policies in the relevant country. Specific indications, doses, liver-monitoring schedules, and contraindications for NK receptor antagonists should be checked against the latest prescribing information and the treating doctor's advice.
Main information sources: FDA / DailyMed prescribing information for fezolinetant and elinzanetant (December 2024 boxed warning for liver injury; revised February 2026); Lederman et al., SKYLIGHT 1 (Lancet 2023), Johnson et al. (JCEM 2023), Neal-Perry et al. (Obstet Gynecol 2023); Pinkerton et al., OASIS 1 & 2 (JAMA 2024-08), OASIS 3 (JAMA Intern Med 2025-09), OASIS 4 (NEJM 2025-06); Nature Reviews Endocrinology 2026 review of NK receptor antagonists (s41574-026-01247-8); pooled elinzanetant safety report at the 2026 ACOG Annual Meeting; FDA approval of elinzanetant 2025-10-24, first global approval by MHRA 2025-07; AbCellera ABCL635 phase II results (2026-08); Gensci GS1-144/Gensci074, Menopause 2025; ENDO 2026 review of nonhormonal VMS treatments; NCCN survivorship recommendations update.
Sources and review scope
- Editorial author
- Gingera Editorial
- Clinical reviewer
- Not yet assigned
- Citation date check
- Pending; source publication dates are not recorded here.
- Risk note
- High: symptom attribution and urgent-care wording require clinician review.
Questions for the clinical reviewer
- Hot flashes and night sweats can occur during the transition.
- New, severe or accompanied symptoms may need evaluation.
Report a content issue
This record lists review questions and citations. It does not mean a clinician has reviewed or approved the article.
Published correction log
- Loading correction history…
Read the source material
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


